UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for psoriasis and psoriatic arthritis in the United Kingdom. Explore treatment pathways including biologics, oral therapies, and novel agents.
Psoriasis affects ~1.8 million people in the UK (~2-3% of the population). It is an autoimmune condition causing red, scaly patches on the skin, often on elbows, knees, scalp, and lower back. About 30% of people with psoriasis develop psoriatic arthritis (joint inflammation). Psoriasis can significantly affect quality of life and is associated with increased cardiovascular risk.
Mild: topical treatments (vitamin D analogues, corticosteroids, coal tar). Moderate: phototherapy (UVB, PUVA). Moderate-severe: systemic therapies - methotrexate, ciclosporin, acitretin, or apremilast (Otezla). Severe: biologic therapies - anti-TNF (adalimumab, etanercept), anti-IL-17 (secukinumab, ixekizumab, brodalumab), anti-IL-23 (guselkumab, risankizumab, tildrakizumab), and anti-IL-12/23 (ustekinumab). NICE recommends biologics for patients with PASI >10 and DLQI >10 who have failed systemic therapy.
Active UK psoriasis trials include: next-generation IL-17/IL-23 inhibitors with longer dosing intervals, oral TYK2 inhibitors (deucravacitinib), JAK inhibitors for psoriatic arthritis, microbiome-based therapies, and precision medicine approaches. The British Association of Dermatologists runs major clinical trials through the UK Dermatology Clinical Trials Network.
Free AI-powered matching - no signup required
Search plaque psoriasis Trials →